Ilyas Sahin, Medical Oncologist at Massachusetts General Hospital, shared on X:
“Exciting news for the pancreatic cancer community: the FDA has accepted the NDA for daraxonrasib in previously treated metastatic pancreatic cancer.
With the application selected for the FDA’s National Priority Voucher program, a decision could potentially come within 1–2 months. Hopefully, full approval will follow soon and bring a much-needed new treatment option for our patients.”
You can also read ‘FDA Accepts Daraxonrasib NDA for Review in Previously Treated Metastatic Pancreatic Cancer‘
